IL162853A0 - The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus - Google Patents
The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitusInfo
- Publication number
- IL162853A0 IL162853A0 IL16285303A IL16285303A IL162853A0 IL 162853 A0 IL162853 A0 IL 162853A0 IL 16285303 A IL16285303 A IL 16285303A IL 16285303 A IL16285303 A IL 16285303A IL 162853 A0 IL162853 A0 IL 162853A0
- Authority
- IL
- Israel
- Prior art keywords
- melagatran
- medicament
- manufacture
- treatment
- type
- Prior art date
Links
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 title 1
- 229960002137 melagatran Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0200198A SE0200198D0 (sv) | 2002-01-23 | 2002-01-23 | New use |
| PCT/SE2003/000087 WO2003061682A1 (en) | 2002-01-23 | 2003-01-21 | The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL162853A0 true IL162853A0 (en) | 2005-11-20 |
Family
ID=20286751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16285303A IL162853A0 (en) | 2002-01-23 | 2003-01-21 | The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7045502B2 (OSRAM) |
| EP (1) | EP1469874A1 (OSRAM) |
| JP (1) | JP2005516035A (OSRAM) |
| KR (1) | KR20040075096A (OSRAM) |
| CN (1) | CN100430089C (OSRAM) |
| BR (1) | BR0306798A (OSRAM) |
| CA (1) | CA2472241A1 (OSRAM) |
| IL (1) | IL162853A0 (OSRAM) |
| MX (1) | MXPA04007192A (OSRAM) |
| NO (1) | NO20043483L (OSRAM) |
| NZ (1) | NZ533749A (OSRAM) |
| SE (1) | SE0200198D0 (OSRAM) |
| WO (1) | WO2003061682A1 (OSRAM) |
| ZA (1) | ZA200405342B (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0200198D0 (sv) * | 2002-01-23 | 2002-01-23 | Astrazeneca Ab | New use |
| JP6155187B2 (ja) | 2010-03-30 | 2017-06-28 | ヴァーセオン コーポレイション | トロンビンの阻害剤としての多置換芳香族化合物 |
| WO2014145986A1 (en) | 2013-03-15 | 2014-09-18 | Verseon, Inc. | Multisubstituted aromatic compounds as serine protease inhibitors |
| ES2791749T3 (es) | 2013-03-15 | 2020-11-05 | Verseon Corp | Halogenopirazoles como inhibidores de la trombina |
| KR20170048410A (ko) | 2014-09-17 | 2017-05-08 | 베르선 코포레이션 | 세린 프로테아제 저해제로서의 피라졸릴-치환된 피리돈 화합물 |
| AU2016224974B2 (en) | 2015-02-27 | 2019-09-26 | Verseon Corporation | Substituted pyrazole compounds as serine protease inhibitors |
| IL280078B2 (en) | 2018-07-13 | 2024-04-01 | Verseon Int Corporation | Thrombin inhibitors, formulations, and uses thereof |
| AU2022325955A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
| JP2025508720A (ja) | 2022-02-17 | 2025-04-10 | サナ バイオテクノロジー，インコーポレイテッド | 遺伝子操作されたｃｄ４７タンパク質及びその使用関連出願の相互参照 |
| AU2024264889A1 (en) | 2023-05-03 | 2025-11-13 | Sana Biotechnology, Inc. | Methods of dosing and administration of engineered islet cells |
| CN121604968A (zh) | 2023-05-22 | 2026-03-03 | 萨那生物科技公司 | 递送胰岛细胞的方法及相关方法 |
| IL326710A (en) | 2023-08-23 | 2026-04-01 | Sana Biotechnology Inc | Modified CD47 proteins and their uses |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9301916D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
| TW541316B (en) | 1995-12-21 | 2003-07-11 | Astrazeneca Ab | Prodrugs of thrombin inhibitors |
| SE9900070D0 (sv) | 1999-01-13 | 1999-01-13 | Astra Ab | New use |
| SE523817C2 (sv) | 1999-02-05 | 2004-05-18 | Corline Systems Ab | Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler |
| US6462021B1 (en) | 2000-11-06 | 2002-10-08 | Astrazeneca Ab | Use of low molecular weight thrombin inhibitor |
| SE0200198D0 (sv) * | 2002-01-23 | 2002-01-23 | Astrazeneca Ab | New use |
-
2002
- 2002-01-23 SE SE0200198A patent/SE0200198D0/xx unknown
-
2003
- 2003-01-21 MX MXPA04007192A patent/MXPA04007192A/es unknown
- 2003-01-21 EP EP03701203A patent/EP1469874A1/en not_active Withdrawn
- 2003-01-21 JP JP2003561625A patent/JP2005516035A/ja active Pending
- 2003-01-21 CN CNB038026740A patent/CN100430089C/zh not_active Expired - Fee Related
- 2003-01-21 IL IL16285303A patent/IL162853A0/xx unknown
- 2003-01-21 BR BR0306798-0A patent/BR0306798A/pt not_active IP Right Cessation
- 2003-01-21 NZ NZ533749A patent/NZ533749A/en unknown
- 2003-01-21 US US10/502,069 patent/US7045502B2/en not_active Expired - Fee Related
- 2003-01-21 WO PCT/SE2003/000087 patent/WO2003061682A1/en not_active Ceased
- 2003-01-21 KR KR10-2004-7011228A patent/KR20040075096A/ko not_active Withdrawn
- 2003-01-21 CA CA002472241A patent/CA2472241A1/en not_active Abandoned
-
2004
- 2004-07-05 ZA ZA2004/05342A patent/ZA200405342B/en unknown
- 2004-08-20 NO NO20043483A patent/NO20043483L/no not_active Application Discontinuation
-
2006
- 2006-02-24 US US11/362,890 patent/US20060148720A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20060148720A1 (en) | 2006-07-06 |
| US7045502B2 (en) | 2006-05-16 |
| US20050090424A1 (en) | 2005-04-28 |
| ZA200405342B (en) | 2005-09-28 |
| CN1729010A (zh) | 2006-02-01 |
| SE0200198D0 (sv) | 2002-01-23 |
| NZ533749A (en) | 2006-02-24 |
| KR20040075096A (ko) | 2004-08-26 |
| BR0306798A (pt) | 2004-12-07 |
| WO2003061682A1 (en) | 2003-07-31 |
| CA2472241A1 (en) | 2003-07-31 |
| CN100430089C (zh) | 2008-11-05 |
| JP2005516035A (ja) | 2005-06-02 |
| EP1469874A1 (en) | 2004-10-27 |
| MXPA04007192A (es) | 2004-10-29 |
| NO20043483L (no) | 2004-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL370818A1 (en) | Dosage form for treatment of diabetes mellitus | |
| AU2003234529A8 (en) | Glp-1 gene delivery for the treatment of type 2 diabetes | |
| EG24124A (en) | Pharmaceutical compositions for the treatment of type-II diabetes mellitus | |
| IL213806A0 (en) | Use of derivatives of n-phenylpiperazin-1-yl-acetamide for the preparation of a pharmaceutical compositions for treatment of diabetes related conditions | |
| MXPA03006936A (es) | Tratamiento de diabetes mellitus. | |
| IL176259A (en) | Use of cystamine in combination with metformin to prepare a cure for diabetes or related complications | |
| AU2003279338A1 (en) | Phenethanolamine derivatives for the treatment of respiratory diseases | |
| TWI345975B (en) | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament | |
| AU2003234929A1 (en) | Therapeutic agent for diabetes | |
| AU2003279442A8 (en) | 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes | |
| PL377164A1 (pl) | Pochodne anilinopirazolu przydatne do leczenia cukrzycy | |
| ZA200405342B (en) | The use of melagatran for the manufacture of a medicament for the treatment of type i diabetes mellitus | |
| AU2003203146A1 (en) | Use of glp-1 compound for treatment of critically ill patients | |
| AU2003252182A1 (en) | Therapeutic treatment for the metabolic syndrome and type 2 diabetes | |
| AU2003303217A8 (en) | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases | |
| AU2003296545A1 (en) | Use of a trpm8-activating substance for the treatment of tumours | |
| AU2562501A (en) | Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders | |
| PL378537A1 (pl) | Zastosowanie propionylo L-karnityny do otrzymywania leku do leczenia glaukomii | |
| AU2003209542A8 (en) | Use of s-substituted l-crysteine for the manufacture of a medicament for the treatment of dermatological disorders | |
| HK1069107A (en) | The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus | |
| GB0212790D0 (en) | Medicament for the treatment of diabetes | |
| AU2002307327A1 (en) | Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes | |
| IL153279A0 (en) | Thiazolidinedione salt for treatment of diabetes mellitus | |
| AU2002311141A1 (en) | The use of hydrochloric acid in the preparation of a medicament for the treatment of tumour | |
| AU2003232698A1 (en) | Use of a n,n'-dibenzyl-thiourea as medicine |